Life sciences · 2025
Investigation of cognitive enhancements and mechanisms of kinsenoside in APP/PS1 mice through network pharmacology, in vivo experiments, and machine learning.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yufeng, Deng Qiqi, Wang Chunxiang, Liang Chengbang, Shi Yu, Liu Xiaoge, Deng Chengeng, Li Jianyu, Zhang Hao, Hua Qian
Аннотация
AIMS: To investigate the therapeutic effects of kinsenoside on cognitive dysfunction in APP/PS1 transgenic mice and to explore its potential targets.
MATERIALS AND METHODS: Network pharmacology was employed to identify targets of kinsenoside in Alzheimer's disease (AD). The Morris water maze test was conducted to assess the therapeutic effects of kinsenoside on cognitive dysfunction in APP/PS1 transgenic mice, and immunofluorescence was used to evaluate the impact of kinsenoside on amyloid-beta (Aβ) pathology and brain lymphatic structure and function. The Raybiotech GSM-CAA-4000 protein chip was used to detect changes in inflammatory factors. Graph convolutional network (GCN) analysis was applied to analyze and identify core targets from the protein chip results, which were then intersected with the network pharmacology findings, followed by molecular docking and molecular dynamics simulations.
RESULTS: Network pharmacology analysis indicated that kinsenoside inhibits inflammation and oxidative stress signaling pathways involved in AD. The maximum neighborhood connectivity (MNC) algorithm identified HSP90AA1, HSP90AB1, PIK3CA, STAT3, IL6, and IFNγ as potential targets. In vivo mouse experiments demonstrated that kinsenoside has the ability to reduce Aβ plaque deposition and expand meningeal lymphatic vessels(mLVs), improving the glymphatic system drainage, which ultimately leads to improved cognitive function. This beneficial effect may be related to the inhibition of IFNγ by kinsenoside.
CONCLUSION: Based on preclinical data, kinsenoside shows promising potential in the treatment of AD.
MATERIALS AND METHODS: Network pharmacology was employed to identify targets of kinsenoside in Alzheimer's disease (AD). The Morris water maze test was conducted to assess the therapeutic effects of kinsenoside on cognitive dysfunction in APP/PS1 transgenic mice, and immunofluorescence was used to evaluate the impact of kinsenoside on amyloid-beta (Aβ) pathology and brain lymphatic structure and function. The Raybiotech GSM-CAA-4000 protein chip was used to detect changes in inflammatory factors. Graph convolutional network (GCN) analysis was applied to analyze and identify core targets from the protein chip results, which were then intersected with the network pharmacology findings, followed by molecular docking and molecular dynamics simulations.
RESULTS: Network pharmacology analysis indicated that kinsenoside inhibits inflammation and oxidative stress signaling pathways involved in AD. The maximum neighborhood connectivity (MNC) algorithm identified HSP90AA1, HSP90AB1, PIK3CA, STAT3, IL6, and IFNγ as potential targets. In vivo mouse experiments demonstrated that kinsenoside has the ability to reduce Aβ plaque deposition and expand meningeal lymphatic vessels(mLVs), improving the glymphatic system drainage, which ultimately leads to improved cognitive function. This beneficial effect may be related to the inhibition of IFNγ by kinsenoside.
CONCLUSION: Based on preclinical data, kinsenoside shows promising potential in the treatment of AD.